Nama's AI scorecard currently rates Glaukos Sell (4.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does GKOS report earnings?

Glaukos's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $0.47.

What is the GKOS price target?

The median analyst price target from 13 analysts is $241.00, with a range of $225.00 – $270.00.

Is GKOS Shariah compliant?

Nama's AAOIFI-style screen reads Glaukos as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Glaukos (GKOS)

Healthcare · Medical Devices · NYSE

Glaukos (GKOS) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $13.28B and a free-cash-flow yield of -0.3%. Over the most recent reported fiscal year, revenue grew 32.3%. Nama's AI scorecard rates it Sell, 4.2 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 4.2/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +110.5% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-12.1%

How far the last close sits under the highest price of the past five years.

Market cap	$13.28B
Trailing P/E	—
Price / book	18.5
Price / sales	19.2
FCF yield	-0.3%
Dividend yield	—
Gross margin	64.8%
Operating margin	-25.3%
Net margin	-24.6%
Revenue growth (YoY)	+32.3%
Revenue growth (3-yr annual)	+21.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.7
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

GKOS earnings

Next report: Feb 16, 2027 (Q4 2026, EPS estimate $0.47). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 28, 2026	$0.47	-$0.09	+622.2%	$211.03M
Q2 2026	Jul 29, 2026	-$0.14	-$0.21	+33.3%	$185.61M
Q1 2026	Apr 29, 2026	-$0.18	-$0.28	+35.7%	$150.57M
Q4 2025	Feb 17, 2026	-$0.28	-$0.20	-40.0%	$143.12M

GKOS analyst price target

Median target $241.00 from 13 analysts, ranging $225.00 – $270.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live GKOS data on Nama Insights →

GKOS FAQ

Is GKOS a buy?: Nama's AI scorecard currently rates Glaukos Sell (4.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does GKOS report earnings?: Glaukos's next scheduled report is on Feb 16, 2027. Analysts expect EPS of $0.47.
What is the GKOS price target?: The median analyst price target from 13 analysts is $241.00, with a range of $225.00 – $270.00.
Is GKOS Shariah compliant?: Nama's AAOIFI-style screen reads Glaukos as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.